Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. - Wikidata - wikimedia - TriplyDB

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

http://www.wikidata.org/entity/Q40368066

about

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Improved nutritional status is related to improved quality of life in Parkinson's disease.A randomized controlled pilot study of the therapeutic effects of yoga in people with Parkinson's disease Objective measurement of dyskinesia in Parkinson's disease using a force plate Analysis of resources assisting in coping with swallowing difficulties for patients with Parkinson's disease: a cross-sectional study.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease Assessing self-awareness of dyskinesias in Parkinson's disease through movie materials.The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease Cost of Living with Parkinson's Disease over 12 Months in Australia: A Prospective Cohort Study.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Emerging drugs for levodopa-induced dyskinesia.Estimating the direct and indirect costs associated with Parkinson's disease.A clinical view on the development of technology-based tools in managing Parkinson's disease.Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.Novel insights in pharmacogenetics of drug response in Parkinson's disease.Sleepwalking, REM sleep behaviour disorder and overlap parasomnia in patients with Parkinson's disease.Self-rated health mediates the association between functional status and health-related quality of life in Parkinson's disease.Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease.A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.Evaluation of the Parkinson's KinetiGraph in monitoring and managing Parkinson's disease.L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.The impact of sleep and mood disorders on quality of life in Parkinson's disease patients.Health-related quality of life among community-dwelling patients with intractable neurological diseases and their caregivers in Japan.Abnormal bidirectional plasticity-like effects in Parkinson's disease.The association of type D personality with quality of life in patients with Parkinson's disease.

P2860

Q24647141-79E13B42-C4AD-4C29-ABAE-0EEBDCA78BAB Q26779605-C7EBEFDB-4E47-4896-ABD3-C60691786204 Q27021464-A9D4DDFA-C8B6-4620-AB92-982570297802 Q34544024-FA44CD9C-2DC1-4526-B91E-BD2ED488F390 Q34780062-E4A07001-5E7E-4B85-B8D3-8BFE7FEF68CF Q35140804-40D4549E-D306-4080-B5CF-E1DB50D0A8D1 Q36081096-9F9149E4-27C9-4A33-955E-280807A22673 Q36573882-48769FE9-5B35-4982-8AE5-9EADB11E0428 Q36708392-9BB028FA-261B-4E17-AC11-F4CC37FF871B Q36866618-1CFD9D6C-AECF-43C1-A589-FBE7CBD8DAE3 Q36992154-E5BE9EF9-E2AF-4DDD-AB09-ABCDCE6FB8D9 Q37271592-B4BF0B82-B0A6-488A-B965-3AAD021DF3F7 Q37491322-619942F5-7FBA-46C4-8C74-8A716038245D Q37703440-D233E43A-CFBF-4412-AB9C-275CDB359177 Q37973462-F3CEA091-E9E2-4542-B085-065BAC52BE0E Q37974709-5C4C2A23-2B78-40CF-A716-6740147A3FC5 Q38212033-527B37ED-10E3-45F9-9D42-6DC039141185 Q38242091-10F015DA-C2B6-4EAE-80B5-DB37EEC5F4A4 Q38618871-15A2F9D1-AD24-4211-A43D-1800F7ED2618 Q38858508-73E55B67-758A-4B6F-BB6F-909F2E27D8A8 Q38981382-43FE07CE-31DA-45D4-9FAC-E47F99117737 Q39107780-016A56FB-2F02-4129-81FC-94FD88428C49 Q39714311-E7A87469-913E-49CA-9B50-FF0507607AD4 Q42167199-E7F4865C-58DB-4ACB-96FD-1327BAD8121E Q43171707-6A39FC7E-C0D3-4686-935A-10B9E4105BEC Q44049630-0029B840-1795-4893-9608-7470DB61C190 Q44590820-6EE043FF-4C00-4B33-AD2A-DC0516174B05 Q44639804-6325D0DD-F993-416D-94DE-4D56AF320407 Q44925523-65B82BC6-CAE8-42AE-A1C3-62A774B2B39B Q45352049-5C1B850A-3895-4292-AE09-39AD0D12323F Q46059323-1B7B982F-5268-4006-BA26-54C540A000CF Q46280394-B091B9D6-4CC7-4258-93D4-73C5E5CF7E68 Q47215658-838550C7-ADE9-4945-82F9-B33D62DCB270 Q47389217-D0BA8F32-5834-45E5-B09A-E79BF189301E Q47557053-C92FBA0B-1BE9-4D74-8393-184D58BB6ED1 Q47615634-8995C026-8D09-4B09-B342-140BE23A753F Q48301186-211042F6-E39E-4281-96A8-53A92A25F5E8 Q48747132-EBD5EC49-4A08-4FEA-AD62-D7C74E713361 Q48829642-109EB51D-65C4-40E1-BDAA-335CB0B95EDC Q48961699-FB3D5963-3569-445D-8EBE-35DF09A149FE

P2860

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

http://www.wikidata.org/entity/Q40368066

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Effects of dyskinesias in Park ...... a prospective European study.

@en

type

label

Effects of dyskinesias in Park ...... a prospective European study.

@en

prefLabel

Effects of dyskinesias in Park ...... a prospective European study.

@en

P1433

Q40368066-32E46308-7C78-40F1-9F83-FA0CD8770FA7

P1476

Q40368066-FA0F9758-9AD1-47A8-ADE1-61255E2E5754

P2093

Q40368066-21AB3A4B-4200-4AC3-BB65-658B4EF927C1

Q40368066-6980DC0E-5314-460E-A914-7D61A27430D9

Q40368066-79ECF41C-DA41-4B43-879A-9FDE224BC559

Q40368066-A0C9CFAD-2CF4-4F05-996F-57C9A64F6820

Q40368066-A5853CB7-973A-4834-8A8B-2E477CEBB575

Q40368066-C93376D7-DDCA-4349-8948-8AA0377F4ABE

Q40368066-E5B4A19D-0CCD-44C6-8843-374C1EE15AEE

P2860

Q40368066-0D361A57-83AD-44DB-B6B9-E4B5325836A6

Q40368066-1572E9D7-F02A-4A04-83F7-3F48DC012DC6

Q40368066-20C4B756-6B38-42AE-93BF-6A1881DA2712

Q40368066-6D6F4D5E-AD33-4A02-B274-D2ED4D27CAB2

Q40368066-98D1DCEC-D418-43EC-AF70-99ED5D08082B

Q40368066-CF22CCBB-D3AF-463D-941E-2A35E72D6A19

Q40368066-FD90EA08-F0A0-44E1-8B30-0EC784BFA40F

P304

Q40368066-DB02EDE6-9A9D-469D-B31D-E343CC1D96C0

P31

Q40368066-A5B400F5-D3F4-424D-BE4A-F50A467FB350

P356

Q40368066-E8E4DDEF-BD2F-41CB-804E-758222B60896

P433

Q40368066-CB9B5AE3-C520-49D5-85EA-AC189D82424F

P478

Q40368066-07E13B88-9384-48F3-A631-2993F0942346

P50

Q40368066-25B81631-748A-4F78-B3ED-E817AF80C29D

P577

Q40368066-54B44FDB-6505-418E-A54F-664B64128AD0

P698

Q40368066-C8A2A07B-AA38-4454-AAFC-368E3F06B006

P921

Q40368066-897C3CA6-B202-4A44-98B4-E45203577995

Q40368066-F792DE38-3EC7-42B2-9422-B24211DB0839

P356

J.1468-1331.2005.01096.X

P1433

European Journal of Neurology

P1476

Effects of dyskinesias in Park ...... : a prospective European study

@en

P2093

B Khoshnood

http://www.w3.org/2001/XMLSchema#string

C Deschaseaux-Voinet

http://www.w3.org/2001/XMLSchema#string

G Berdeaux

http://www.w3.org/2001/XMLSchema#string

M Péchevis

http://www.w3.org/2001/XMLSchema#string

M Ziegler

http://www.w3.org/2001/XMLSchema#string

P Vieregge

http://www.w3.org/2001/XMLSchema#string

Trial Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

How should cost data in pragmatic randomised trials be analysed?

Evaluating drug treatments for Parkinson's disease: how good are the trials?

The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.

Health related quality of life in Parkinson's disease: a prospective longitudinal study

Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.

The health burdens of Parkinson's disease.

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

P304

956-963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1331.2005.01096.X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16324089

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease